PTC Therapeutics (NASDAQ:PTCT) Shares Down 6.7% – Here’s Why

PTC Therapeutics, Inc. (NASDAQ:PTCT) shares were down 6.7% on Monday . The company traded as low as $71.15 and last traded at $72.3010. Approximately 383,301 shares were traded during mid-day trading, a decline of 73% from the average daily volume of 1,443,200 shares. The stock had previously closed at $77.53.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

Wall Street Analyst Weigh In

PTCT has been the topic of a number of research analyst reports. Jefferies Financial Group boosted their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Wells Fargo & Company upped their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Barclays lifted their price objective on PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Finally, The Goldman Sachs Group upped their target price on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $77.27.

PTC Therapeutics Stock Performance

The stock has a 50 day moving average of $76.61 and a two-hundred day moving average of $62.91. The firm has a market capitalization of $6.23 billion, a P/E ratio of 9.06 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. During the same quarter in the prior year, the business earned ($1.39) earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. Sell-side analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Insiders Place Their Bets

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 71,928 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $83.44, for a total transaction of $6,001,672.32. Following the completion of the sale, the insider directly owned 100,625 shares in the company, valued at $8,396,150. This represents a 41.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan Steven Jacobson sold 14,199 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $83.55, for a total transaction of $1,186,326.45. Following the completion of the sale, the director owned 17,451 shares in the company, valued at approximately $1,458,031.05. The trade was a 44.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 287,633 shares of company stock worth $22,674,765 in the last ninety days. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On PTC Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Empowered Funds LLC bought a new position in PTC Therapeutics in the first quarter worth $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of PTC Therapeutics by 11.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock valued at $9,109,000 after buying an additional 18,504 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of PTC Therapeutics by 62.8% during the 1st quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock worth $2,003,000 after acquiring an additional 15,167 shares during the period. Acadian Asset Management LLC boosted its position in shares of PTC Therapeutics by 6.1% during the 1st quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock valued at $1,904,000 after acquiring an additional 2,140 shares in the last quarter. Finally, Strs Ohio bought a new stake in PTC Therapeutics in the first quarter valued at about $438,000.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.